SLC5A2 and diabetes mellitus: Sodium-dependent glucose transporter-2 (SGLT-2) inhibitors have been a popular topic in research on diabetes drugs in recent years.[7] SGLT-2 regulates blood glucose through the excretion function of the kidneys in addition to the metabolic pathway of glucose in the body by means of increasing the excretion of glucose by the kidneys.[8] SGLT-2 inhibitors are approved in many countries to treat diabetes.